Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group
R. Donald Harvey(Emory University), Thomas S. Uldrick(Regeneron (United States)), Kathryn F. Mileham(Levine Cancer Institute), Elizabeth Ness(Center for Cancer Research), Cassadie Moravek(Pancreatic Cancer Action Network), Atiqur Rahman(Linköping University), Jamie R. Brewer(Center for Democracy in the Americas), Vishal Bhatnagar(Yashoda Hospital), S. Percy Ivy(National Cancer Institute), Caroline Schenkel(American Society of Clinical Oncology), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), E. Claire Dees(University of North Carolina at Chapel Hill), Andrew S. Kennedy(Sarah Cannon)
Cited by 29
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k